Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3995MR)

This product GTTS-WQ3995MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3995MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11803MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ6182MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ6777MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ14345MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ11712MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ8158MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ13993MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ4285MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW